Amarantus BioScience Holdings, Inc. AMBS

AMBS Company Overview

Amarantus BioScience Holdings, Inc. (OTC: AMBS) was a biotechnology company focused on diagnostics, regenerative medicine, and therapeutic development targeting neurodegenerative diseases, ophthalmology, and infectious disease applications. The company operated primarily through a portfolio model that combined internally developed technologies with acquired biotechnology assets. Its activities centered on biomarker-based diagnostics, stem cell-related technologies, and biologic therapeutics intended for conditions with significant unmet medical need.

The company’s principal business lines historically included the development of the LymPro Test for Alzheimer’s disease diagnostics, regenerative medicine programs associated with NuroPro and MANF technologies, and specialty therapeutic assets acquired through subsidiaries and licensing arrangements. Amarantus evolved through a series of acquisitions, licensing deals, and subsidiary formations beginning in the early 2010s, transitioning from an early-stage biotechnology platform into a holding structure overseeing multiple clinical and preclinical programs. Public disclosures and market reporting indicate that the company experienced financial and operational challenges in later years, and current operational activity appears limited based on available public filings.